Table 9.
Test 2: Adverse Event Rates
| Treatment-Emergent Diabetes | Treatment-Emergent Hyperlipidemia | |||||||
| New Event Rate* (Base Case Rate) |
Total Mean Cost | QALYs | ICER Cost/QALYs | New Event Rate** (Base Case Value) |
Total Mean Cost | QALYs | ICER Cost/QALYs | |
| OLZ | 4.6% (3.3%) |
$8567 | 0.733 | Dominant | 21.8% (16.8%) |
$8582 | 0.731 | Dominant |
| RIS | 4.1% (3.2%) |
$9095 | 0.719 | - | 21.4% (14.0%) |
$9122 | 0.717 | - |
| QUE | 4.3% (3.6%) |
$13628 | 0.708 | - | 21.3% (14.1%) |
$13666 | 0.706 | - |
| ZIP | 4.1% (2.0%) |
$11445 | 0.715 | - | 19.6% (8.1%) |
$11478 | 0.711 | - |
| ARIP | 4.1% (2.0%) |
$11632 | 0.710 | - | 16.7% (3.6%) |
$11678 | 0.707 | - |
*Source: Leslie and Rosenheck, 2005 [84]
**Source: Olfson et al., 2006 [70]
QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio; OLZ = olanzapine; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole
Further analysis showed that olanzapine remained dominant when the rates of diabetes for aripiprazole and ziprasidone were kept at the base case value and all others were increased.